M3 Inc

M3: Guidance Points to Further Slowdown in Growth

271 Views01 May 2023 17:43
M3's 4Q earnings were below consensus and guidance for FY03/24E revenue growth is the lowest in more than 2 decades. slowdown in pharma mktg and overseas biz and end of Covid trials are downside risks
(Sign Up to Access)
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
  • Unlock all research summaries
  • Follow top, independent analysts
  • Receive personalised alerts and emails
  • Access Briefings, Analytics, and Events

Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.

Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.

Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 3-minute read)
(Paid Plans Only)